ARCHIVES

FDA Advisors Unanimously Turn Down GPC Biotech’s Orplatna for Prostate Cancer.

This article is from The Cancer Letter archive.

Vol. 33 No. 29 | July 27, 2007

Download PDF Visit The Full Archive

Related Articles

In Brief: Fishman La Jolla President Emeritus, Ruoslahti Succeeds Him; Ariz. Seeks Meyskins Replacement

January 13, 1989

Clinical Trials Approved By NCI During November Are Listed

December 27, 2002

High Risk Youth Targeted In Concept Ok’d By Advisors

February 8, 1991

In Brief: Hew Approves Patent Request From U. Arizona; Califano Still Pondering Bioassay Program Fate

September 1, 1978

Litton Wins FCRF Research Contract, Harland Land Animal Protections

September 17, 1982

Response From Center Representatives In L.A. To NCI Questions Is “Frusterating,” DeVita Says

April 13, 1984